PROTEIN CONSTRUCT BASED ON A RECEPTOR-SPECIFIC MUTANT VARIANT OF THE ANTITUMOR CYTOKINE TRAIL AS A HYBRID PROTEIN WITH A PEPTIDE SPECIFIC FOR INTEGRIN ΑVΒ3 FOR THE TREATMENT OF SOLID TUMORS Russian patent published in 2023 - IPC C07K19/00 A61K38/19 A61P35/00 

FIELD: biotechnology; medicine; oncology.

SUBSTANCE: invention can be used for the treatment of various tumor diseases. The following is proposed: a hybrid protein construct containing a receptor-selective variant of the TRAIL cytokine, which specifically binds to the DR5 death receptor at the N-terminus of the polypeptide chain, and a peptide that specifically binds to integrin αvβ3 at the C-terminus, which provides increased accumulation in tumors. The construct is used as an active ingredient in pharmaceutical compositions intended for the treatment of oncological diseases characterized by the expression of the DR5 receptor and integrin αvβ3 on the surface of tumor cells such as glioblastoma, pancreatic adenocarcinoma and others.

EFFECT: due to the bispecificity, the invention provides faster accumulation in tumor structures and an increased level of efficacy compared to the DR5-specific mutant variant of the antitumor cytokine TRAIL.

7 cl, 6 dwg, 6 ex